Exhibit 99.1

Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results

Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025").

Q4 FY 2025 Company Highlights

FY 2025 Company Highlights

“Fiscal year 2025 was a banner year for Electromed – posting record revenues and profitability as our diverse growth initiatives yielded strong results,” said Jim Cunniff, President, and Chief Executive Officer. “Our direct sales and fulfillment model continues to be a key differentiator for Electromed in the airway clearance space. During the year, we strengthened our operational infrastructure with key new hires, and we allocated meaningful resources to improve operational efficiencies. Specifically, we began a manufacturing optimization plan to increase capacity that we expect to complete in fiscal year 2026 and have begun deploying a new CRM system designed to enhance our sales team’s efficiency and productivity. As in previous years, we continued to strategically expand our direct sales team in geographies where we expect high returns, while executing various initiatives to raise awareness of bronchiectasis, which is a disease that is misdiagnosed and underdiagnosed. Our strong results clearly demonstrate the important role HFCWO therapy plays in treating this awful disease, and we will continue to advance Electromed’s vision of being the most trusted provider in the airway clearance space.”

Q4 FY 2025 Results

All amounts below are for the three months ended June 30, 2025 and compare to the three months ended June 30, 2024.

Net revenues grew 17.3% to $17.4 million, from $14.8 million.

Revenue in our direct homecare business increased 14.8% to $15.4 million, from $13.4 million. The increase in revenue was primarily due to incremental referrals and approvals driven by an increase in direct sales representatives as well as higher net revenues per approval. 

Gross profit increased to $13.6 million or 78.3% of net revenues from $11.3 million or 76.2% of net revenues. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $10.3 million representing an increase of $1.5 million or 17.0%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process higher patient referrals.

Operating income was $3.0 million or 17.5% of net revenues, compared to $2.3 million, or 15.7% of net revenues. This increase in operating income was primarily due to an increase in revenue and gross profit.

Net income increased by 20.6% to $2.2 million, or $0.25 per diluted share, compared to $1.8 million, or $0.20 per diluted share.

FY 2025 Summary

All amounts below are for the year ended June 30, 2025 ("fiscal 2025") and compare to the fiscal year ended June 30, 2024 ("fiscal 2024").

Net revenues for fiscal 2025 grew by 17.0% to a record $64.0 million, from $54.7 million in fiscal 2024.

Revenue in our direct homecare market increased year-over-year by 15.7% to $57.3 million, from $49.5 million. The increase in revenue was due to an increase in direct sales representatives and higher net revenues per approval. Field sales employees totaled 62 at year end, 55 of which were direct sales representatives. The annualized homecare revenue per weighted average direct sales representative in FY 2025 was $1,058,000, slightly higher than Electromed’s target range of $900,000 to $1,000,000.

Revenue in our non-homecare business grew to $6.7 million in fiscal 2025, an increase of $1.5 million, or 28.8%, from $5.2 million in fiscal 2024. The increase was primarily due to increased distributor and hospital revenue.

Gross profit increased to $50.0 million, or 78.1% of net revenues in fiscal 2025, from $41.7 million, or 76.3% of net revenues, in fiscal 2024. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $39.3 million in fiscal 2025, representing an increase of $4.8 million or 14.0% from $34.5 million in fiscal 2024. The increase was primarily due to increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process higher patient referrals.

Operating income was $9.7 million or 15.1% of net revenues in fiscal 2025, compared to $6.6 million, or 12.0% of net revenues in fiscal 2024.  This increase in operating income was primarily due to increases in net revenues and gross profit.

Net income for fiscal 2025 was $7.5 million, or $0.85 per diluted share, compared to $5.2 million, or $0.58 per diluted share in fiscal 2024. 

As of June 30, 2025, Electromed had $15.3 million in cash, $24.7 million in accounts receivable and no debt, achieving a working capital of $34.6 million and total shareholders’ equity of $43.2 million. The cash balance reflects a decrease of $0.8 million for the twelve months ended June 30, 2025, compared to an increase in cash of $8.7 million in the twelve months ended June 30, 2024. The decrease in cash for the twelve months ended June 30, 2025, was driven by share repurchases of Electromed common stock totaling $10.0 million and $2.3 million of taxes paid in connection with net settlements and forfeitures of vested equity awards. These cash outflows were offset by $11.4 million of cash generated from operating activities, which represents an increase of $2.3 million over the prior year.

Conference Call and Webcast Information

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, August 26, 2025.

Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1726358&tp_key=03c4e0b55a

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 10201085. Additionally, an online replay will be available for at least one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “continue,” “expect,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include,  but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases and changes to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Brad Nagel, Chief Financial Officer
(952) 758-9299
[email protected]

Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
[email protected]

Source: Electromed, Inc.

Electromed, Inc.

Condensed Balance Sheets

Electromed, Inc.

Condensed Statements of Operations

Electromed, Inc.

Condensed Statements of Cash Flows

Exhibit 99.2

Forward Looking Statements Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include,  but are not limited to, competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; component or raw material shortages; changes to lead times or changes to trade regulations; wage and component price inflation; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; technical problems with our research and products; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Electromed – Who We Are  Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives.  Headquarters:New Prague, MN  Ticker:ELMD  Established:1992  Annual Revenue:$64.0M  Market Cap:$187M  Share Count:8.5M  179 Employees Manufacturing in Minnesota  HFCWO Market Focus

a. Electromed Highlights - Growing and profitable medical technology company  - A leader in the large and expanding airway clearance market - The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement -Attractive direct-to-patient and provider model  -Strong financial profile with attractive gross margins and well-capitalized balance sheet - 33% Operating Income CAGR* FY’21 Revenue = $35.8, FY’21 Operating Income = $3.1, FY’22 Revenue = $41.7, FY’22 Operating Income = $3.0, FY’23 Revenue =  $48.1, FY’23 Operating Income = $4.0, FY’24 Revenue =  $54.7, FY’24 Operating Income = $6.5, FY'25 Revenue =  $64.0, FY’25 Operating Income = $9.7 (Amounts in millions)

What is Bronchiectasis (BE)?  Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways)  Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways  Mean prevalence of bronchiectasis in patients with COPD is 54%¹  Disease Misdiagnosed  Disease Underdiagnosed  HFCWO Under-prescribed  1.Chalmers J. and Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18

U.S. Market: Large, Growing, Underpenetrated  Estimated HFCWO bronchiectasis penetration, treated population3 ~148k HFCWO ADOPTED3 Bronchiectasis HFCWO penetration ~16%3  Estimated Net Bronchiectasis prevalence, DIAGNOSED1 ~923k U.S. BE Diagnosed1 Diagnosed BE population growing at ~12% annually1  Estimated bronchiectasis prevalence, UNDIAGNOSED with COPD/BE overlap2 4.1 million U.S. Undiagnosed2 35% of BE patients managed by pulmonologists1  1Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database  2Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data  3Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database, GUIDEHOUSE 2023 literature review and 2024 S2N HFCWO Claims data

How is Bronchiectasis Treated?  Antibiotics, Anti-Inflammatories, Airway Clearance  

How is Bronchiectasis Treated?  HFCWO Therapy – Mimics Manual CPT  

SmartVest Clearway®  HFCWO Designed with the Patient in Mind  An Enhanced Patient Experience  Sleek and light weight generator  Intuitive user interface for better patient adherence  More portable and easier for travel  SmartVest® has a well-established reimbursement code from CMS – E0483; We estimate we have over 250 million contracted lives in the US

SmartNotes™ Patient Progress Report  Patient Outcomes and Treatment Progress to Physicians  SmartNotes combine patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management  TeleRespiratory Services: A team of Respiratory Therapists stay connected with patients and support their therapy utilization.  Outcomes Management: Easy-to-read report provides physicians with a comprehensive view of disease progression and therapy impact.

Clinical Evidence  Electromed has Published Studies Showing Effectiveness of HFCWO to Treat Bronchiectasis  Therapy with SmartVest® significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function. Powner (2018)  Therapy with HFCWO demonstrated key health outcomes improved in post- compared to pre-index period: cough, all-cause hospitalizations, pneumonia, and pulmonary hospitalizations. DeKoven (2022)  57% Reduction in antibiotic prescriptions1  59% Decrease in hospitalizations1  75% Fewer emergency department visits2  1.Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38.  2. Sievert CE, et al 2018. Incidence of Bronchiectasis-Related Exacerbation Rates After HFCWO Treatment—A Longitudinal Outcome-Based Study, Respiratory Therapy, 13(2), 38-41.

Direct-to-Patient Model  Drives Attractive Margin Profile  Traditional Medical Equipment Channel  Direct-to-Patient Distribution (Electromed) Company expects gross margins in the mid-70s and improving with the SmartVest® Clearway®  Manufacturer $ DME $ Patient vs. Electromed $$ Patient

Net Revenue Breakdown - $64.0M (TTM ended 6/30/2025) - By Setting: 1% (Other), 5% (Hospitals), 94% (Home Care, includes $2.9M from home care distributor revenue). Homecare By Payer: 2% (Medicaid), 46% (Medicare), 52% (Commercial/Other, Includes Managed Medicare and Managed Medicaid). Homecare Qualified Referral Volume: 2% (Other), 20% (Neuromuscular), 3% (Cystic Fibrosis), 75% (Bronchiectasis).

Growth Strategy  How Will Electromed Increase Market Share?  Continued sales force expansion along with complementary infrastructure investments  Increase brand awareness and revenue with direct-to-consumer and physician marketing  Market development to improve diagnosis rates and evidence to support the adoption of the SmartVest system for patients  SmartAdvantage™ best-in-class customer care and support  Expand e-prescribing capability

Long-Term Objectives  Electromed is committed to delivering long-term profitable growth  Double-digit Revenue Growth Increase market share Deeper penetration of current SmartVest prescribers  Operating Margin Improvement Operating leverage as revenue increases

Capital Allocation Strategy  Proven execution against our priorities  Capital Allocation Support organic business growth Generate Free Cash Flow  Potential Strategic Investments Strategic M&A Opportunities  or  Return to Shareholders Share Buybacks  2025 Execution New CRM & CAPEX investments Sales rep expansion Market development Triple Down on BE campaign Product enhancements  $10.0 million of shares repurchased in FY25

Why Invest?  Large, expanding chronic lung diseases market  Clinically proven technology  Broad payor coverage  Consistent double-digit organic revenue growth  High gross margins, robust cash flow and expanding operating leverage

Performance vs. Russell Medical Equipment Index  (TTM and as of 6/30/2025 Results)  Metric ELMD vs. RUS ME:  Sales Growth: 17.0% > 11.7%,  Gross Margin: 78.1% > 51.6%,  Operating Margin: 15.1% > (3.5%)

Jim Cunniff, President & CEO (952) 758-9299 [email protected]  Brad Nagel, CFO (952) 758-9299 [email protected]  Mike Cavanaugh (617) 877-8641 [email protected]

APPENDIX

Financial Summary Year Ended (in $ millions, except shares amounts) June 30, 2024 June 30, 2025:  Revenues: FY24: $54.7 FY25: $64.0,  Gross Profit: FY24 $41.7 FY25: $50.0,  Gross margin FY24: 76% FY25: 78%,  Operating income: FY24: $6.6 FY25: $9.7,  Operating margin: FY24: 12% FY25: 15%,  Net income: FY24: $5.2 FY25: $7.5,  Diluted EPS: FY24: $0.58 FY25: $0.85,  Diluted Shares: FY24: 8,864,585 FY25: 8,914,421,  Cash provided by operations: FY24: $9.1 FY25: $11.4